Table 2.
Demographics Table for RPA risk Groups for TCGA Cohort
| Group 1 (N = 327) | Group2 (N = 75) | Group 3 (N = 176) | Group 4 (N = 188) | Total (N = 766) | |
|---|---|---|---|---|---|
| Clinical and Demographics Variables | |||||
| Sex | |||||
| Female | 128 (39.1%) | 38 (51.4%) | 68 (41.7%) | 73 (42.9%) | 307 (41.8%) |
| Male | 199 (60.9%) | 36 (48.6%) | 95 (58.3%) | 97 (57.1%) | 427 (58.2%) |
| Age at diagnosis | |||||
| Mean (SD) | 60.5 (11.9) | 41.1 (10.6) | 42.3 (12.5) | 40.0 (12.4) | 49.7 (15.4) |
| Median | 61.0 | 44.0 | 40.0 | 38.5 | 51.0 |
| Q1, Q3 | 54.5, 69.0 | 34.2, 50.0 | 33.0, 51.0 | 30.0, 49.8 | 37.0, 61.0 |
| Range | 14.0–88.0 | 10.0–54.0 | 20.0–75.0 | 14.0–74.0 | 10.0–88.0 |
| Grade | |||||
| II | 6 (1.8%) | 10 (13.5%) | 52 (31.9%) | 113 (66.5%) | 181 (24.7%) |
| III | 38 (11.6%) | 19 (25.7%) | 91 (55.8%) | 57 (33.5%) | 205 (27.9%) |
| IV | 283 (86.5%) | 45 (60.8%) | 20 (12.3%) | 0 (0.0%) | 348 (47.4%) |
| WHO grouping | |||||
| IDH-mutant Astrocytoma | 0 (0.0%) | 0 (0.0%) | 86 (48.9%) | 117 (62.2%) | 203 (29.0%) |
| IDH-mutant GBM | 0 (0.0%) | 0 (0.0%) | 20 (11.4%) | 0 (0.0%) | 20 (2.9%) |
| IDH-mutant oligodendroglioma | 0(0.0%) | 0 (0.0%) | 70 (39.8%) | 71 (37.8%) | 141 (20.1%) |
| IDH-wildtype astrocytoma | 43 (15.8%) | 29 (46.0%) | 0 (0.0%) | 0 (0.0%) | 72 (10.3%) |
| IDH-wildtype GBM | 230 (84.2%) | 34 (54.0%) | 0 (0.0%) | 0 (0.0%) | 264 (37.7%) |
| IDH status | |||||
| Wildtype | 273 (100.0%) | 63(100.0%) | 0 (0.0%) | 0 (0.0%) | 336 (48.0%) |
| Mutant | 0 (0.0%) | 0 (0.0%) | 176 (100.0%) | 188 (100.0%) | 364 (52.0%) |
| ATRX status | |||||
| Wildtype | 170 (52.0%) | 36 (48.0%) | 98 (55.7%) | 105 (55.9%) | 409 (53.4%) |
| Mutant | 9 (2.8%) | 3 (4.0%) | 67 (38.1%) | 83 (44.1%) | 162 (21.1%) |
| Vital status | |||||
| Alive | 53 (16.2%) | 26 (34.7%) | 126 (71.6%) | 175 (93.1%) | 380 (49.6%) |
| Deceased | 274 (83.8%) | 49 (65.3%) | 50 (28.4%) | 13 (6.9%) | 386 (50.4%) |
| Survival time (years) | |||||
| Median | 1.03 | 2.14 | 5.29 | 14.14 | 2.50 |
| 95% CI | (0.97 to 1.16) | (2.04 to 3.92) | (4.21 to 7.64) | (9.50 to NA) | (2.16 to 3.13) |
| SDL risk | |||||
| Mean (SD) | 1.2 (0.7) | 0.2 (1.1) | −0.2 (0.7) | −1.7 (0.6) | 0.1 (1.3) |
| Median | 1.3 | 0.6 | −0.3 | −1.6 | 0.2 |
| Q1, Q3 | 1.0, 1.6 | 0.1, 0.9 | −0.7, 0.2 | −1.9, −1.3 | −1.0, 1.3 |
| Range | −1.4 to 2.8 | −4.9 to 1.1 | −1.0 to 1.5 | −3.9 to -1.0 | −4.9 to 2.8 |
Abbreviations: IDH, isocitrate dehydrogenase 1 or 2 gene; ATRX, α-thalassemia, mental retardation, X-linked protein; 1p19q, deletion status of short arm of chromosome 1 and long arm of chromosome 19; GBM, glioblastoma multiforme; SDL risk, survival deep learning risk; RPA, recursive partitioning analysis.